<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544410</url>
  </required_header>
  <id_info>
    <org_study_id>SPR001-204</org_study_id>
    <secondary_id>CAHmelia 204</secondary_id>
    <nct_id>NCT04544410</nct_id>
  </id_info>
  <brief_title>A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spruce Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spruce Biosciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid&#xD;
      dosing in classic CAH subjects up to 76 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study that will evaluate the ability of Tildacerfont to reduce the glucocorticoid&#xD;
      steroid dose used by adult CAH subjects. The first 24-weeks will be a double-blind, placebo&#xD;
      controlled, comparison of Tildacerfont vs Placebo. The following 52-weeks will allow all&#xD;
      subjects to move to open label Tildacerfont to continue to reduce steroid dose where&#xD;
      appropriate, and observe long term safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 1:1 manner to either Tildacerfont or Placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GC dose at Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Absolute change from baseline in GC dose in HCe at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GC use adjusted for body surface area in subjects with CAH</measure>
    <time_frame>24 weeks</time_frame>
    <description>Absolute change from baseline in GC dose in HCe in mg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the median cumulative HCe dose in subjects with CAH</measure>
    <time_frame>76 Weeks</time_frame>
    <description>Median total cumulative GC dose in HCe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GC use while maintaining control of A4 in subjects with CAH</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Composite endpoint:&#xD;
Absolute change from baseline in GC dose in HCe in subjects who maintain A4 ≤ ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in supraphysiologic GC use to physiologic GC use while maintaining control of A4 in subjects with CAH</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Composite endpoint:&#xD;
Proportion of subjects with GC dose ≤20 mg/day in HCe in subjects who maintain A4 ≤ ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GC toxicity in subjects with CAH</measure>
    <time_frame>24 weeks</time_frame>
    <description>Glucocorticoid Toxicity Index Aggregate Improvement Score (GTI-AIS) (Miloslavsky 2017)&#xD;
Score range: -346 to 439 A positive score means worsening and a negative score means improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters (fat mass) in subjects with CAH</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in fat mass as measured by dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters (body weight) in subjects with CAH</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters (homeostatic model assessment of insulin resistance) in subjects with CAH</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in homeostatic model assessment of insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tildacerfont Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tildacerfont administered daily via oral tablet for 76 weeks at dose level 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered daily via oral tablet for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tildacerfont/Placebo</intervention_name>
    <description>Tablet, administered daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tildacerfont Group</arm_group_label>
    <other_name>SPR001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects over 18 years old, inclusive&#xD;
&#xD;
          -  Has a documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency&#xD;
             based on genetic mutation in CYP21A2 and/or elevated 17-OHP&#xD;
&#xD;
          -  Has been on a stable, supraphysiologic dose of GC replacement for ≥1 month before&#xD;
             screening without any evidence of non-adherence to the GC regimen during this period.&#xD;
&#xD;
          -  For subjects with the salt-wasting form of CAH, subject has been on a stable dose of&#xD;
             mineralocorticoid replacement for ≥1 month before screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known or suspected diagnosis of any other known form of classic CAH (not due to&#xD;
             21-hydroxylase deficiency)&#xD;
&#xD;
          -  Has a history that includes bilateral adrenalectomy or hypopituitarism&#xD;
&#xD;
          -  Has a history of allergy or hypersensitivity to tildacerfont, any of its excipients,&#xD;
             or any other CRF1 receptor antagonist&#xD;
&#xD;
          -  Shows clinical signs or symptoms of adrenal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Newfield, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rady Children's Hospital-San Diego and Professor of clinical pediatrics at UC San Diego School of Medicine.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>415-655-4169</phone>
    <email>CAH_ClinicalTrials@sprucebiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Camp Springs</city>
        <state>Maryland</state>
        <zip>20746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Biosciences Clinical Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>99702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Study Site</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clarahealth.com/studies/cahmelia</url>
    <description>CAHmelia screening website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAH</keyword>
  <keyword>Adrenal Disorder</keyword>
  <keyword>Congenital Adrenal Hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

